FDA approves 2nd RSV vaccine for older adults

The FDA approved the second respiratory syncytial virus vaccine for adults 60 and older on May 31. 

The vaccine, Pfizer's Abrysvo, is a bivalent shot approved to prevent lower respiratory tract disease caused by RSV, according to a news release from the drugmaker. 

GSK received the first approval for an RSV shot May 3 with its Arexvy vaccine. 

There are no approved RSV vaccines for children, another population vulnerable to the virus.

Copyright © 2023 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars